Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus.

Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus.

Ebola virus (EBOV) causes severe and often fatal hemorrhagic fever in humans and nonhuman primates (NHPs). Currently, there are no licensed vaccines or therapeutics for human use. Recombinant vesicular stomatitis virus (rVSV)-based vaccine vectors, which encode an EBOV glycoprotein in place of the V...

Full description

Bibliographic Details
Main Authors:	Chad E Mire, Joan B Geisbert, Andrea Marzi, Krystle N Agans, Heinz Feldmann, Thomas W Geisbert
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2013-01-01
Series:	PLoS Neglected Tropical Diseases
Online Access:	http://europepmc.org/articles/PMC3868506?pdf=render

Similar Items

Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates.
by: Chad E Mire, et al.
Published: (2014-01-01)

Use of Single-Injection Recombinant Vesicular Stomatitis Virus Vaccine to Protect Nonhuman Primates Against Lethal Nipah Virus Disease
by: Chad E. Mire, et al.
Published: (2019-06-01)

Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates.
by: Thomas W Geisbert, et al.
Published: (2008-11-01)

Vesicular Stomatitis Virus–Based Vaccines against Lassa and Ebola Viruses
by: Andrea Marzi, et al.
Published: (2015-02-01)

<italic toggle="yes">Bundibugyo ebolavirus</italic> Survival Is Associated with Early Activation of Adaptive Immunity and Reduced Myeloid-Derived Suppressor Cell Signaling
by: Courtney Woolsey, et al.
Published: (2021-08-01)

A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.
by: David Safronetz, et al.
Published: (2015-04-01)

Vesicular Stomatitis Virus-Based Vaccine Protects Mice against Crimean-Congo Hemorrhagic Fever
by: Sergio E. Rodriguez, et al.
Published: (2019-05-01)

Nonhuman Primates Are Protected against Marburg Virus Disease by Vaccination with a Vesicular Stomatitis Virus Vector-Based Vaccine Prepared under Conditions to Allow Advancement to Human Clinical Trials
by: Christopher L. Cooper, et al.
Published: (2022-09-01)

A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge.
by: Courtney Woolsey, et al.
Published: (2022-05-01)

Recombinant vesicular stomatitis virus–vectored vaccine induces long-lasting immunity against Nipah virus disease
by: Courtney Woolsey, et al.
Published: (2023-02-01)

Natural history of nonhuman primates after conjunctival exposure to Ebola virus
by: Robert W. Cross, et al.
Published: (2023-03-01)

Natural history of Sudan ebolavirus infection in rhesus and cynomolgus macaques
by: Courtney Woolsey, et al.
Published: (2022-12-01)

Evaluation in Nonhuman Primates of Vaccines against Ebola Virus
by: Thomas W. Geisbert, et al.
Published: (2002-05-01)

Transcriptional correlates of disease outcome in anticoagulant-treated non-human primates infected with ebolavirus.
by: Sara Garamszegi, et al.
Published: (2014-01-01)

Reversion of Ebolavirus Disease from a Single Intramuscular Injection of a Pan-Ebolavirus Immunotherapeutic
by: Erin Kuang, et al.
Published: (2022-06-01)

Combination therapy with remdesivir and monoclonal antibodies protects nonhuman primates against advanced Sudan virus disease
by: Robert W. Cross, et al.
Published: (2022-05-01)

Enhanced light microscopy visualization of virus particles from Zika virus to filamentous ebolaviruses.
by: George G Daaboul, et al.
Published: (2017-01-01)

The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials
by: Ellen Suder, et al.
Published: (2018-09-01)

Transcriptome Analysis of Circulating Immune Cell Subsets Highlight the Role of Monocytes in Zaire Ebola Virus Makona Pathogenesis
by: Andrea R. Menicucci, et al.
Published: (2017-10-01)

Development of an acute and highly pathogenic nonhuman primate model of Nipah virus infection.
by: Thomas W Geisbert, et al.
Published: (2010-05-01)

Correction for Olsen et al., “Polyamines and Hypusination Are Required for Ebolavirus Gene Expression and Replication”
by: Michelle E. Olsen, et al.
Published: (2018-07-01)

A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates.
by: Benoit Callendret, et al.
Published: (2018-01-01)

Correction: A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates.
by: Benoit Callendret, et al.
Published: (2018-01-01)

Assessment of the ability of V920 recombinant vesicular stomatitis-Zaire ebolavirus vaccine to replicate in relevant arthropod cell cultures and vector species
by: Nicholas A. Bergren, et al.
Published: (2018-04-01)

Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs.
by: Nancy J Sullivan, et al.
Published: (2006-06-01)

Rapid protection of nonhuman primates against Marburg virus disease using a single low-dose VSV-based vaccineResearch in context
by: Kyle L. O'Donnell, et al.
Published: (2023-03-01)

Monoclonal antibody therapy demonstrates increased virulence of a lineage VII strain of Lassa virus in nonhuman primates
by: Courtney Woolsey, et al.
Published: (2024-12-01)

Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever.
by: Andrea Marzi, et al.
Published: (2012-01-01)

Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment
by: Robert W. Cross, et al.
Published: (2020-07-01)

Long-Term Single-Dose Efficacy of a Vesicular Stomatitis Virus-Based Andes Virus Vaccine in Syrian Hamsters
by: Joseph Prescott, et al.
Published: (2014-01-01)

Enterovirus vesicular stomatitis with exanthema: Epidemiological Features and Vaccination
by: Yu. S. Sytaya, et al.
Published: (2022-07-01)

Tamoxifen Protects from Vesicular Stomatitis Virus Infection
by: Lamin B. Cham, et al.
Published: (2019-09-01)

A VP35 Mutant Ebola Virus Lacks Virulence but Can Elicit Protective Immunity to Wild-Type Virus Challenge
by: Courtney Woolsey, et al.
Published: (2019-09-01)

Immunological correlates of protection afforded by PHV02 live, attenuated recombinant vesicular stomatitis virus vector vaccine against Nipah virus disease
by: Thomas P. Monath, et al.
Published: (2023-09-01)

Recombinant Protein Filovirus Vaccines Protect Cynomolgus Macaques From Ebola, Sudan, and Marburg Viruses
by: Axel T. Lehrer, et al.
Published: (2021-08-01)

High dose of vesicular stomatitis virus-vectored Ebola virus vaccine causes vesicular disease in swine without horizontal transmission
by: Igor Morozov, et al.
Published: (2021-01-01)

Vesicular Stomatitis Virus: From Agricultural Pathogen to Vaccine Vector
by: Guodong Liu, et al.
Published: (2021-08-01)

Evaluating Temperature Sensitivity of Vesicular Stomatitis Virus–Based Vaccines
by: Derek R. Stein, et al.
Published: (2019-08-01)

Vaccine delivery with microneedle skin patches in nonhuman primates
by: Li, Adrienne Victoria, et al.
Published: (2014)

The use of nonhuman primate models in HIV vaccine development.
by: Cecilia Morgan, et al.
Published: (2008-08-01)